What is the difference between Emgality and Nurtec ODT?

Same class. Both Emgality and Nurtec ODT are CGRP inhibitors, so they work through the same broad mechanism. Differences between them tend to be about dosing, route, how selective they are, and side effects rather than what they target.

Are Emgality and Nurtec ODT the same drug?

No. Emgality is the brand name for Galcanezumab and Nurtec ODT is the brand name for Rimegepant. They are different active ingredients.

Is Emgality a tablet or an injection?

Emgality is given by the subcutaneous route; Nurtec ODT by the oral route.

Who makes Emgality and Nurtec ODT?

Emgality is marketed by Eli Lilly; Nurtec ODT by Pfizer. (FDA application holder, per Drugs@FDA.)

Emgality vs Nurtec ODT: How Galcanezumab and Rimegepant Compare

Reviewed by the Priya Life Science Editorial Team, led by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from official FDA data · Last verified 6 Aug 2026 · Editorial standards

At a glance

EmgalityGalcanezumab

Nurtec ODTRimegepant

Brand names

Emgality

Nurtec ODT / Vydura

Drug class

CGRP inhibitor

CGRP receptor antagonist

Route

Subcutaneous

Oral

Marketed by

Eli Lilly

Pfizer

First FDA approval

27 Sep 2018

27 Feb 2020

US shortage

Not listed

Key differences

Same class. Both Emgality and Nurtec ODT are CGRP inhibitors, so they work through the same broad mechanism. Differences between them tend to be about dosing, route, how selective they are, and side effects rather than what they target.
How they are taken. Emgality is given by the subcutaneous route; Nurtec ODT by the oral route.
Time on the market. Emgality was first approved by the FDA in 2018, Nurtec ODT in 2020. That gives Emgality roughly 2 more years of real-world use and long-term safety data.
Who markets them. Emgality is marketed by Eli Lilly; Nurtec ODT by Pfizer.
Same drug, more than one brand. Rimegepant is sold as Nurtec ODT / Vydura — the same active ingredient marketed under different brand names, typically for different approved uses or doses.

What each one treats

EmgalityGalcanezumab

EMGALITY ® is a calcitonin-gene related peptide antagonist indicated in adults for the: preventive treatment of migraine. ( 1.1 ) treatment of episodic cluster headache. ( 1.2 ) 1.1 Migraine EMGALITY is indicated for the preventive treatment of migraine in adults. 1.2 Episodic Cluster Headache EMGALITY is indicated for the treatment of episodic cluster headache in adults.

Nurtec ODTRimegepant

NURTEC ODT is a calcitonin gene-related peptide receptor antagonist indicated for the: acute treatment of migraine with or without aura in adults ( 1.1 ) preventive treatment of episodic migraine in adults ( 1.2 ) 1.1 Acute Treatment of Migraine NURTEC ODT is indicated for the acute treatment of migraine with or without aura in adults . 1.2 Preventive Treatment of Episodic Migraine NURTEC ODT is indicated for the preventive treatment of episodic migraine in adults.

How each one works

EmgalityCGRP inhibitor

12.1 Mechanism of Action Galcanezumab-gnlm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.

Nurtec ODTCGRP receptor antagonist

12.1 Mechanism of Action Rimegepant is a calcitonin gene-related peptide receptor antagonist.

Related comparisons

Aimovig VS Emgality Aimovig VS Nurtec ODT Emgality VS Ajovy Emgality VS Ubrelvy Ajovy VS Nurtec ODT Nurtec ODT VS Ubrelvy

Emgality profile Nurtec ODT profile CGRP Inhibitors All comparisons

This is not a recommendation of one drug over the other.

Which medicine is right for a given person depends on their diagnosis, other conditions, other medicines, kidney and liver function, pregnancy, and cost or reimbursement — none of which this page knows. Two drugs in the same class are not automatically interchangeable. Never start, stop or switch a prescription medicine on the basis of a web page; that decision belongs to you and your clinician or pharmacist.

How this page is built

The facts on this page are pulled directly from official U.S. FDA datasets — they are not written from memory. Each field below names the dataset it came from, so you can check it yourself.

FDA Drug Label (openFDA) ↗ Indications, mechanism of action and pharmacologic class
Drugs@FDA ↗ First FDA approval date and the company holding the application
FDA Drug Shortage Database ↗ Current US supply / shortage status

Plain-English summaries and drug-class explainers are written and reviewed by the Priya Life Science editorial team, led by Sreepriya Prasannan (MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany). Data is retrieved automatically from the sources above and cross-checked with AI-assisted verification (Anthropic's Claude) — brand and generic names are matched against the exact FDA product record so that a combination product or a different formulation cannot be mistaken for the drug on this page. An editor reviews the result before publication. We describe this in full in our editorial standards and corrections policy. The FDA data on this page was last retrieved on 6 Aug 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Emgality vs Nurtec ODT